A Multicenter, Randomized, Open-Label,Phase 2 Trial of Donafenib in 131I-Refractory Differentiated Thyroid Cancer
Phase of Trial: Phase II
Latest Information Update: 12 Oct 2017
At a glance
- Drugs Donafenib (Primary)
- Indications Thyroid cancer
- Focus Therapeutic Use
- Sponsors Suzhou Zelgen Biopharmaceuticals
- 09 Oct 2017 Planned End Date changed from 1 Dec 2019 to 1 Dec 2018.
- 09 Oct 2017 Planned primary completion date changed from 1 Dec 2018 to 1 Dec 2017.
- 09 Oct 2017 Status changed from not yet recruiting to recruiting.